Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective study of Bendamustine-Bortezomib-Desametasone (BVD) in patients with Relapsed and Refractory Multiple Myeloma

Next Previous
Trial Profile

A Retrospective study of Bendamustine-Bortezomib-Desametasone (BVD) in patients with Relapsed and Refractory Multiple Myeloma

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Pegfilgrastim
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 19 Jan 2017 New trial record
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top